Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;11(3):701-710.
doi: 10.1007/s13300-020-00758-5. Epub 2020 Feb 4.

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes

Fu-Ping Lyu  1   2 , Bing-Kun Huang  1   2 , Wei-Juan Su  1   2 , Fang-Fang Yan  1   2 , Jin-Yang Zeng  1   2 , Zheng Chen  1   2 , Yu-Xian Zhang  1   2 , Shun-Hua Wang  1   2 , Yin-Xiang Huang  2   3 , Mu-Lin Zhang  2   3 , Xiu-Lin Shi  1   2 , Ming-Zhu Lin  4   5   6 , Xue-Jun Li  7   8   9
Affiliations

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes

Fu-Ping Lyu et al. Diabetes Ther. 2020 Mar.

Abstract

Introduction: The aim of this study was to compare the efficacy of vildagliptin as add-on therapy to short-term continuous subcutaneous insulin infusion (CSII) with CSII monotherapy in hospitalized patients with type 2 diabetes mellitus (T2DM).

Methods: A total of 200 hospitalized patients with inadequately controlled T2DM were randomized into groups, with one group receiving CSII monotherapy (CSII group, n =100) and the other group receiving CSII plus vildagliptin as add-on (CSII + Vig group, n = 100). Of these, 191 completed the 7-day trial (CSII group, n = 99; CSII + Vig group, n = 92) and included in the analysis. The glycemic control and variability of the patients were measured using all-day capillary blood glucose (BG) monitoring. Weight and fasting C-peptide levels were evaluated before and after the interventions.

Results: Mean BG concentrations during the whole treatment period were lower and the time to reach target BG was reduced in the CSII + Vig group compared with the CSII group (9.89 ± 3.37 vs. 9.46 ± 3.23 mmol/L, P < 0.01; 129 ± 4 vs. 94 ± 5 h, P < 0.01, respectively). Similarly, the indicators of glycemic variability, namely the standard deviation of BG and the largest amplitude of glycemic excursion, were significantly decreased in the CSII + Vig group compared with the CSII group (2.68 ± 1.05 vs. 2.39 ± 1.00 mmol/L, P < 0.01; 7.19 ± 2.86 vs. 6.23 ± 2.73 mmol/L, P < 0.01, respectively).

Conclusions: Short-term CSII with vildagliptin as add-on therapy may be an optimized treatment for hospitalized patients with T2DM compared with short-term CSII monotherapy.

Keywords: Continuous subcutaneous insulin infusion; Dipeptidyl peptidase-4 inhibitors; Glycemic variability; Hypoglycemia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of patient inclusion throughout the trial. CSII continuous subcutaneous insulin infusion monotherapy group, CSII+Vig group CSII therapy plus vildagliptin as add-on group
Fig. 2
Fig. 2
Comparison of the daily changes in mean blood glucose (MBG) level between the CSII and CSII+Vig groups. Data are presented as the mean ±  standard deviation (SD). MBG refers to the MBG concentration of each day during treatment
Fig. 3
Fig. 3
Overall changes in blood glucose (BG) during the daytime between the CSII and CSII+Vig groups. Data are presented as the mean ± SD. BG refers to the MBG concentration of each regular measurement
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28–34. doi: 10.1016/S2213-8587(13)70006-8. - DOI - PubMed
    1. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753–1760. doi: 10.1016/S0140-6736(08)60762-X. - DOI - PubMed
    1. Lv WS, Li L, Wen JP. Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients. Int J Endocrinol. 2013;2013:614242. doi: 10.1155/2013/614242. - DOI - PMC - PubMed
    1. Yang H, Heng X, Liang C, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus. J Int Med Res. 2014;42(4):1002–1010. doi: 10.1177/0300060514533523. - DOI - PubMed
    1. Pastores SM. ACP Journal Club. Review: Intensive insulin therapy does not reduce mortality but increases severe hypoglycemia in hospitalized patients. Ann Intern Med. 2011;155(2):JC1–12. - PubMed

LinkOut - more resources